| Patient | Yul Brynner |
|---|---|
| Date of birth | 1963-07-11 |
| Identifiers | MRN HR-ML020-SYN; SSN (made up) 000-20-4572 |
| Document date | 2026-10-27 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; rash improving. [S]
Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe on first-line pembrolizumab every 3 weeks (two cycles so far) and zoledronic acid every 12 weeks, who comes for his yearly preventive visit, timed before the respiratory virus season. The rash seen last week is fading with the triamcinolone cream, and the itching is much less; he has used cetirizine on three nights. He has had no new symptoms of immune-related side effects. His voice is stronger after the injection medialization and voice therapy, and he has begun rehearsing two hours a day; he hopes to rejoin the tour for a few performances a week next month. He saw the palliative care team four weeks ago and found it useful. He completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit |
| Active treatment | Pembrolizumab every 3 weeks; zoledronic acid every 12 weeks; vitamin D3 daily |
| Interval change | Rash fading on topical steroid; no other immune-related symptoms |
| Work | Rehearsing two hours a day; plans a graded return to the tour |
| Supports | Spouse, company manager, and the palliative care team |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, apart from tiring by evening |
| Psychosocial | Worried about the future but coping; strong sense of purpose in returning to the stage; supportive spouse and company |
| Tobacco | Former smoker; no tobacco for 12 years |
| Alcohol and drugs | A glass of wine two or three nights a week (AUDIT-C 2); no other drug use |
| Physical activity | Walks 30 minutes most days and does stage warm-ups |
| Nutrition | Eating well; weight stable at about 72 kg |
| Sleep | About seven hours a night; itching woke him twice last week |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; company manager handles travel bookings |
| Home and travel safety | Smoke detectors at home; seat belt always; hotel rooms booked near elevators |
| Falls | None |
| Hearing and vision | Reading glasses; no hearing difficulty |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by evening; no fever, night sweats, or weight loss since starting treatment |
| Eyes | Negative | No redness or change in vision |
| Ears, nose, mouth, and throat | Positive | Voice still slightly breathy after a long rehearsal; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Positive | Occasional dry cough in the morning; mild breathlessness on two flights of stairs, unchanged |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or blood in the stool |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No back, hip, or rib pain |
| Integumentary | Positive | Rash fading; mild itch |
| Neurological | Negative | No headache, weakness, or numbness |
| Psychiatric | Negative | Mood steady; PHQ-2 score 1 |
| Endocrine | Negative | No heat or cold intolerance or excessive thirst |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks | Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel | Intravenous route | 2026-09-22 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases | Every 12 weeks, after calcium and creatinine, with a dental examination done first | Intravenous route | 2026-10-13 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid | One tablet by mouth daily | Oral route | 2026-10-13 | active | S |
| Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) | Apply a thin layer twice daily for up to two weeks | Topical route | 2026-10-20 | active | S |
| Cetirizine 10 mg oral tablet, one tablet daily as needed for itching | One tablet by mouth daily as needed for itching | Oral route | 2026-10-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 178 | cm | S |
| 2026-10-27 | Body weight | 72.3 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 74 | /min | S |
| 2026-10-27 | Respiratory rate | 16 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-27 | Total score [AUDIT-C] | 2 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well, upright, and commanding; weight 72.3 kg, BMI 22.8 |
| Eyes | Pupils equal and reactive; conjunctivae normal |
| Ears, nose, and throat | Voice louder and less breathy than at presentation; oral mucosa normal; good dentition |
| Neck | No supraclavicular or cervical nodes; thyroid not enlarged |
| Cardiovascular | Regular rhythm at 74 per minute; no murmur; no edema |
| Respiratory | Slightly reduced breath sounds at the left apex; no wheeze or crackles |
| Abdomen | Soft and non-tender; no liver enlargement |
| Musculoskeletal | No spinal, pelvic, or rib tenderness |
| Skin | Fading pink macules on the chest and back; no new lesions; no suspicious moles |
| Neurological | Alert and oriented; normal strength and gait |
| Psychiatric | Composed and engaged; good insight |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
| Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement) | active | confirmed | L27.0 | S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | Inactivated vaccine given today; safe on checkpoint inhibitor therapy |
| Pneumococcal vaccine | Completed today | PCV20 given today; recommended once for all adults 50 and older |
| Recombinant zoster vaccine | Completed today | Dose 1 given today; dose 2 in two to six months |
| COVID-19 vaccine, this season | Due | Recommended; at his pharmacy next week, spaced from today's vaccines at his request |
| RSV vaccine | Due | Recommended at 60 to 74 for adults at increased risk, which his lung cancer confers; planned for the next visit |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap six years ago |
| Colorectal cancer screening | Due | Recommended at 45 to 75; deferred by shared decision while he starts treatment for metastatic cancer; to be revisited after the first response scan |
| Prostate cancer screening | Declined | Individual decision at 55 to 69; after discussion he declined PSA testing while on cancer treatment |
| Lung cancer screening | Not indicated | He has lung cancer and is followed with response imaging |
| Abdominal aortic aneurysm screening | Not indicated | One-time ultrasound for men 65 to 75 who have ever smoked; he is 63, and his staging CT showed a normal abdominal aorta |
| Hepatitis C and HIV screening | Up to date | One-time screening for both done in the past, negative |
| Cholesterol screening and statin decision | Due | Deferred by shared decision while he starts treatment for metastatic cancer |
| Diabetes screening | Up to date | Glucose is checked before each pembrolizumab infusion; 94 to 104 mg/dL |
| Blood pressure screening | Completed today | 124/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 4 two weeks ago |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 2, below the risk threshold |
| Tobacco use | Completed today | Former smoker; no tobacco for 12 years |
| Skin examination | Completed today | Rash fading; no suspicious lesions |
Immunizations given today: Influenza vaccine, 2026-2027 season; Pneumococcal conjugate vaccine PCV20, single dose; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Cycle 3 of pembrolizumab next week. COVID-19 vaccine at the pharmacy next week. Response CT in about four weeks. RSV vaccine and zoster dose 2 at later visits. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 30 minutes, with his consent, building on the goals-of-care conversation with the palliative care team. We talked about what metastatic lung cancer can mean, that treatment aims to control it and help him live well for as long as possible rather than to cure it, and why it helps to plan ahead while he is well. He named a health care agent, who is recorded in the chart and not named here, and took a health care proxy form and a living will form home. He said what matters most to him is to keep working on the stage for as long as he can and to be told the truth plainly. He wants full cancer treatment now. He chose not to record other specific treatment preferences today. The plan will be revisited at the first response scan and at any change in his health. [S]